FEB 06, 2018 10:56 AM PST

Scientists Use Robotics to Create Effective HIV Vaccines

WRITTEN BY: Kara Marker

Scientists continue to build upon a vaccine candidate to prevent HIV infection, the virus that causes AIDS. AIDSVAX was first developed and tested in the 90s, but now a University of California Santa Cruz scientist is working on perfecting it. Using new robotics technology, researchers are making the vaccine development process more effective and more productive, cutting costs and saving time all the while.

Scanning electromicrograph of an HIV-infected T cell. Credit: NIAID

"Dozens of interesting vaccine candidates have been described, but most have not been tested in humans because it has not previously been possible to manufacture them affordably and in a timely fashion," explained Phil Berman from the University of California Santa Cruz. "The technology we developed should break the logjam in HIV vaccine development, because it tremendously shortens the time, improves the yield, and lowers the cost."

Berman is talking about the multitude of problems many scientists have faced while tackling the production of an effective vaccine to prevent HIV. The virus’s envelope proteins are difficult to imitate and include in a vaccine, which is needed to stimulate the immune system and build immunity against the virus.

Using robotics, Berman and his team were able to make a variety of improvements on the AIDSVAX vaccine and the developmental process:

  1. Decrease the time required to produce stable cell lines, which are necessary for making HIV envelope proteins, an important “ingredient” of an HIV vaccine
  2. Increase the amount of protein the cell lines can produce
  3. Reduce equipment and material costs

Berman was also successful in creating cell lines that make HIV envelope proteins with the right kind of carbohydrate components - glycans - needed for an effective immune response.

"The conventional way of making these envelope protein vaccines incorporated the wrong kind of carbohydrates,” Berman explained. “We now know that destroyed many of the important antigenic sites recognized by protective antibodies."

Glycans are the unique carbohydrates found on HIV envelope proteins. Berman and his team used CRISPR/Cas9 gene editing technology to create a new cell line called “MGAT CHO” that produces the right kind of glycans. Additionally, the process turned out to be simpler and less expensive than others used to recover and purify proteins.

"People used to think carbohydrates are not immunogenic, but HIV turns everything on its head, and it turns out that the most important antibodies are directed to this unusual carbohydrate," Berman said. "We can now make vaccines with it for the first time.”

Berman hopes that the improvements made on the HIV vaccine will improve its efficacy from 31 percent to more than 50 percent. He currently has two cell lines ready to produce vaccines on a large scale, and he is looking for funding to conduct clinical trials.

Sources: aidsmap, University of California Santa Cruz

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
OCT 19, 2021
Drug Discovery & Development
Researchers develop a potent antiviral drug for dengue fever
OCT 19, 2021
Researchers develop a potent antiviral drug for dengue fever
Dengue fever is a mosquito borne illness that is widespread, especially in tropical countries. The global incidence of d ...
DEC 16, 2021
Immunology
Just Add Water: Super Stable Freeze-Dried COVID Vaccines
DEC 16, 2021
Just Add Water: Super Stable Freeze-Dried COVID Vaccines
  In the face of a viral threat with pandemic potential, developing a potent vaccine is just one half of the battle ...
DEC 27, 2021
Cancer
Improving Immunotherapy with a Novel Nanoparticle
DEC 27, 2021
Improving Immunotherapy with a Novel Nanoparticle
Malignant pleural effusion (MPE) occurs in cancer patients experiencing a buildup of fluid and tumor cells in the pleura ...
JAN 14, 2022
Health & Medicine
First Genetically-Altered Pig Heart Transplanted to a Human
JAN 14, 2022
First Genetically-Altered Pig Heart Transplanted to a Human
Doctors have performed the first successful transplantation of a pig heart into a human. David Bennett, a 57-year-old ma ...
JAN 20, 2022
Health & Medicine
Transverse Myelitis Listed as a Side Effect of AstraZeneca's Viral Vector COVID-19 Vaccine, Recommended for J&J's Vaccine
JAN 20, 2022
Transverse Myelitis Listed as a Side Effect of AstraZeneca's Viral Vector COVID-19 Vaccine, Recommended for J&J's Vaccine
After reviewing data, the European Medicines Agency (EMA) concludes there is a likely causal relationship between the UK ...
JAN 26, 2022
Drug Discovery & Development
Oral Immunotherapy Puts Peanut Allergy into Remission
JAN 26, 2022
Oral Immunotherapy Puts Peanut Allergy into Remission
Peanut oral immunotherapy may help young children who are highly allergic to peanuts become desensitized to their allerg ...
Loading Comments...